

**O I P E**  
MAR 02 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date 2/28/05 below.

Dated: 2/28/05 Signature: (Ginn Blundell)

Docket No.: WIBL-P01-010  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Sabatini et al.

Application No.: 10/782244

Confirmation No.: 5817

Filed: February 18, 2004

Art Unit: 1653

For: mTOR KINASE-ASSOCIATED PROTEINS

Examiner: A. B. Rooke

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Applicant believes no fee is due with this response in addition to the fees provided for on the Fee Transmittal sheet. However, if a fee is due, please charge our Deposit Account No. 18-1945, from which the undersigned is authorized to draw, under Order No. WIBL-P01-010.

Dated: February 28, 2005

Respectfully submitted,

By 

Z. Angela Guo

Registration No.: 54,144

ROPES & GRAY LLP


One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Patent Information Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	10/782244
				Filing Date	February 18, 2004
				First Named Inventor	David M. Sabatini
				Art Unit	1653
				Examiner Name	A. B. Rooke
Sheet	1	of	2	Attorney Docket Number	WIBL-P01-010

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Chen, J., et al., "Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue," Proc. Natl. Acad. Sci. USA, 92:4947-4951 (1995).		
	CB	Dennis, P.B., et al., "Mammalian TOR: A Homeostatic ATP Sensor," Science, 294:1102-1105 (2001).		
	CC	Gao, X., et al., "Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling," Nature Cell Biology, 4:699-704 (2002).		
	CD	Hara, K., et al., "Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action," Cell, 110:177-189 (2002).		
	CE	Hentges, K.E., et al., "FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse," PNAS, 98(24):13796-13801 (2001).		
	CF	Keith, C.T. and Schreiber, S.L., Science 270 (5233): 50-1 (abstract)		
	CG	Kim, D-H., et al., "GβL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR," Molecular Cell, 11:895-904 (2003).		
	CH	Kim, D-H., et al., "mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery," Cell, 110(2):163-175 (2002).		
	CI	Kwiatkowski, D.J., et al., "A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells," Human Molecular Genetics, 11(5):525-534 (2002).		
	CJ	Liu, Z., et al., "RTG-dependent mitochondria to nucleus signaling is negatively regulated by the seven WD-repeat protein Lst8p," The EMBO Journal, 20(24):7209-7219 (2001).		
	CK	Mammalian Gene Collection (MGC) Program Team: "Generation and Initial Analysis of More Than 15,000 Full-Length Human and Mouse cDNA Sequences", Proceedings of the National Academy of Sciences of USA, National Academy of Science, 99(26): 16899-16903 (2002)		
	CL	Neshat, M.S., et al., "Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR," PNAS, 98(18):10314-10319 (2001).		
	CM	Nojima, H., et al., "The Mammalian Target of Rapamycin (mTOR) Partner, Raptor, Binds the		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

9663037\_1



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/782244
				Filing Date	February 18, 2004
				First Named Inventor	David M. Sabatini
				Art Unit	1653
				Examiner Name	A. B. Rooke
Sheet	2	of	2	Attorney Docket Number	WIBL-P01-010


		mTOR Substrates p70 S6 Kinase and 4E-BP1 through Their TOR Signaling (TOS) Motif," Journal of Biological Chemistry, 278(18):15461-15464 (2003).	
	CN	Ochotorena, I.L., et al., "Conserved Wat1/Pop3 WD-repeat protein of fission yeast secures genome stability through microtubule integrity and may be involved in mRNA maturation," Journal of Cell Science, 114:2911-2920 (2001).	
	CO	Podsypanina, K., et al., "An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice," PNAS, 98(18):10320-10325 (2001).	
	CP	Riken Genome Exploration Research Group Phase II Team and Fantom Consortium: "Functional Annotation of a Full-Length Mouse CDNA Collection", Nature, MacMillan Journals Ltd., London, GB, 409(6821): 685-690 (2001)	
	CQ	Roberg, K.J., et al., "Control of Amino Acid Permease Sorting in the Late Secretory Pathway of Saccharomyces cerevisiae by SEC13, LST4, LST7 and LST8," Genetics, 147:1569-1584 (1997).	
	CR	Rodgers, B.D., et al., "Insulin regulation of a novel WD-40 repeat protein in adipocytes," Journal of Endocrinology, 168:325-332 (2001).	
	CS	Sabatini, D.M., et al., "RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs," Cell, 78(1):35-43 (1994) abstract.	
	CT	Sarbassov, Dos D., et al., "Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton", Current Biology, 14: 1296-1302 (2004)	
	CU	Schmeizie, T., et al., "TOR, a Central Controller of Cell Growth," Cell, 103:253-262 (2000).	
	CV	Vogt, P.K., "PI 3-kinase, mTOR, protein synthesis and cancer," Trends in Molecular Medicine, 7(11):482-484 (2001).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

9663037\_1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application No. (if known): 10/782244

Attorney Docket No.: WIBL-P01-010

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on February 28, 2005  
Date

Signature

Ginny Blundell

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 951-7000  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (22 References, CA - CV)